Range of suitable clients: CDEC talked over the uncertainty in the volume of patients with reasonably severe to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be labeled as obtaining delicate or moderate illness may have a severe bleeding phenotype,